Manchester United PLC (MANU) EPS Estimated At $0.11; Shorts at Adaptimmune Therapeutics Plc Ads (ADAP) Raised By 34.42%

August 30, 2017 - By Clifton Ray

Analysts expect Manchester United PLC (NYSE:MANU) to report $0.11 EPS on September, 11.They anticipate $0.04 EPS change or 57.14% from last quarter’s $0.07 EPS. MANU’s profit would be $18.05M giving it 37.39 P/E if the $0.11 EPS is correct. After having $-0.05 EPS previously, Manchester United PLC’s analysts see -320.00% EPS growth. The stock decreased 0.60% or $0.1 on August 29, reaching $16.45. About shares traded. Manchester United PLC (NYSE:MANU) has risen 0.85% since August 30, 2016 and is uptrending. It has underperformed by 15.85% the S&P500.

Adaptimmune Therapeutics Plc Ads (NASDAQ:ADAP) had an increase of 34.42% in short interest. ADAP’s SI was 457,700 shares in August as released by FINRA. Its up 34.42% from 340,500 shares previously. With 183,100 avg volume, 3 days are for Adaptimmune Therapeutics Plc Ads (NASDAQ:ADAP)’s short sellers to cover ADAP’s short positions. The SI to Adaptimmune Therapeutics Plc Ads’s float is 0.99%. The stock increased 0.17% or $0.01 during the last trading session, reaching $6.01. About shares traded. Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has declined 43.56% since August 30, 2016 and is downtrending. It has underperformed by 60.26% the S&P500.

Among 5 analysts covering Manchester United Ltd. (NYSE:MANU), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Manchester United Ltd. had 11 analyst reports since September 18, 2015 according to SRatingsIntel. On Monday, June 5 the stock rating was maintained by Jefferies with “Buy”. Credit Suisse maintained Manchester United PLC (NYSE:MANU) rating on Tuesday, March 15. Credit Suisse has “Outperform” rating and $20 target. Jefferies maintained Manchester United PLC (NYSE:MANU) rating on Friday, September 18. Jefferies has “Buy” rating and $21 target. Jefferies maintained the stock with “Buy” rating in Monday, August 14 report. The stock of Manchester United PLC (NYSE:MANU) has “Buy” rating given on Monday, October 17 by Gabelli. The firm earned “Buy” rating on Tuesday, August 16 by Jefferies.

Manchester United plc is engaged in the operation of a professional football club together with related and ancillary activities. The company has market cap of $2.70 billion. The Company’s football activities primarily comprise various activities, such as its first team, reserve team, youth academy, global scouting networks and other operations, such as its sport science, medical and fitness activities at the Aon Training Complex. It has a 149.9 P/E ratio. It operates in three sectors, including Commercial, Broadcasting and Matchday.

Investors sentiment decreased to 1.38 in Q4 2016. Its down 0.31, from 1.69 in 2016Q3. It turned negative, as 5 investors sold Manchester United PLC shares while 9 reduced holdings. 11 funds opened positions while 12 raised stakes. 28.66 million shares or 0.79% more from 28.44 million shares in 2016Q3 were reported. 45,025 are owned by Roundview Limited Liability Com. Blackrock Institutional Trust Na holds 324 shares or 0% of its portfolio. Moreover, Da Davidson Com has 0% invested in Manchester United PLC (NYSE:MANU). D E Shaw Inc holds 0.01% or 231,793 shares in its portfolio. Retail Bank Of Montreal Can has invested 0% in Manchester United PLC (NYSE:MANU). Jupiter Asset Management Ltd holds 1.47% or 2.77 million shares. Wells Fargo Mn, California-based fund reported 4,460 shares. Moreover, Kj Harrison & Partners has 0.15% invested in Manchester United PLC (NYSE:MANU) for 27,229 shares. Tower Research Capital Ltd Company (Trc) accumulated 2,056 shares. Millennium Management Limited Liability Co stated it has 0% of its portfolio in Manchester United PLC (NYSE:MANU). Savings Bank Of America Corporation De holds 21,870 shares. California Public Employees Retirement Systems has invested 0% in Manchester United PLC (NYSE:MANU). 15,600 are held by Connable Office. Lomas Management Limited Liability Co has invested 2.65% in Manchester United PLC (NYSE:MANU). Morgan Stanley, New York-based fund reported 175,427 shares.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The company has market cap of $562.05 million. The Firm is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor T-cell platform. It currently has negative earnings. The Firm has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.